Group 1 - The company Jinling Pharmaceutical announced the convening of its second extraordinary general meeting of shareholders for 2025 on August 8, 2025 [2] - The meeting approved multiple proposals, including the proposal to add non-independent directors [2]

Core Viewpoint - The legal opinion letter confirms that the procedures for convening and holding the 2025 Second Extraordinary General Meeting of Jinling Pharmaceutical Co., Ltd. comply with relevant laws and regulations, ensuring the legitimacy of the meeting and its outcomes [2][5][9]. Group 1: Meeting Procedures - The meeting was convened in accordance with the provisions of the Company Law, the Shareholders' Meeting Rules, and the Company's Articles of Association [2][4]. - The notice for the meeting was published on the official website and included details such as time, location, and voting methods [3]. - The meeting utilized a combination of on-site and online voting, with specific time frames for online participation [3][4]. Group 2: Attendance and Qualifications - A total of 4 shareholders and their proxies attended the on-site meeting, along with company directors, supervisors, and senior management [4]. - 196 shareholders participated in the online voting, representing 42,767,369 shares, which is 6.8569% of the total shares [4]. - The qualifications of all attendees and the meeting conveners were verified and deemed valid [4][6]. Group 3: Voting Procedures and Results - The voting was conducted through a combination of on-site and online methods, with results announced immediately after the voting concluded [6][9]. - The proposal for the issuance of restricted stock received 99.8798% approval from the total voting rights represented at the meeting [6]. - The voting results for small shareholders showed a 99.1518% approval rate for the same proposal [6][7]. Group 4: Conclusion - The legal opinion concludes that the meeting's convening, attendance, and voting procedures were all in compliance with applicable laws and regulations, affirming the legitimacy of the meeting and its resolutions [9][10].

金陵药业股份有限公司章程 （1998 年 9 月实施；2003 年 6 月第一次修订；2004 年 12 月第二次 修订；2005 年 5 月第三次修订；2006 年 4 月第四次修订；2007 年 8 月第五次修订；2008 年 6 月第六次修订；2009 年 2 月第七次修订； 2010 年 5 月第八次修订；2012 年 8 月第九次修订；2014 年 6 月第十 次修订；2017 年 12 月第十一次修订；2018 年 5 月第十二次修订；2020 年 6 月第十三次修订；2020 年 12 月第十四次修订；2021 年 11 月第 十五次修订；2022 年 1 月第十六次修订；2022 年 3 月第十七次修订； 2022 年 6 月第十八次修订；2023 年 2 月第十九次修订；2024 年 4 月 第二十次修订;2025 年 8 月第二十一次修订） 第一章 总 则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组 织和行为，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限 ...

证券代码：000919 证券简称：金陵药业 公告编号：2025-055 金陵药业股份有限公司关于 回购注销限制性股票减少注册资本 股票数量合计为 178.41 万股。本次回购注销首次授予限制性股票的 价格为 3.29 元/股，回购注销预留授予限制性股票的价格为 4.29 元/ 股，回购价款总计 6,075,789 元，资金来源为自有资金。本次回购注 销完成后，公司股份总数将由623,708,628股减少至621,924,528股， 公司注册资本也将由 623,708,628 元减少至 621,924,528 元。具体内 容详见《金陵药业股份有限公司关于调整 2021 年限制性股票激励计 划回购价格及回购注销激励对象已获授但尚未解除限售的限制性股 票的公告》（公告编号：2025-049）。 二、需债权人知晓的相关信息 由于公司本次回购注销限制性股票将导致注册资本减少，根据 《中华人民共和国公司法》（以下简称"《公司法》"）等相关法律、 法规的规定，公司特此通知债权人，债权人自接到公司通知之日起 30 日内、未接到通知的自本公告披露之日起 45 日内，有权要求本公 司清偿债务或者提供相应的担保。债权人未在规定期限 ...

特别提示： 证券代码：000919 证券简称：金陵药业 公告编号：2025-054 金陵药业股份有限公司 2025 第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1、本次会议没有出现否决议案的情形。 2、本次会议没有涉及变更前次股东大会决议的情形。 一、会议召开和出席的情况 1、会议召开的情况 （1）召开时间 现场会议召开时间：2025 年 8 月 8 日 14:00 网络投票时间：通过深圳证券交易所（以下简称"深交所"）交 易系统进行网络投票的具体时间为：2025年8月8日9:15-9:25，9:30 －11:30和13:00－15:00。通过深交所互联网投票系统进行网络投票 的时间为：2025年8月8日9:15－15:00。 （2）现场会议召开地点：南京市中央路 238 号公司本部六楼会 议室 （3）召开方式：采取现场投票与网络投票相结合的方式 （4）召集人：公司董事会 （5）现场会议主持人：董事长陈胜先生 （6）本次股东大会的召集与召开程序、出席会议人员资格及表 决程序，符合《公司法》《深圳证券交易所股票上市规则》等法律、 ...

江苏泰和律师事务所 关于金陵药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 泰和津师事务所 JC MASTER LAW OFFICES 中国 · 南京 · 清江南路70号国家水资源大厦9层 电话: 025 84503333 传真: 025 84505533 网址: http: //www.jcmaster.com 法律意见书 江苏泰和律师事务所 关于金陵药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：金陵药业股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》（以下简称"《公 司法》"）、中国证券监督管理委员会《上市公司股东会规则》（以下简称"《股 东会规则》"）等法律、法规、规范性文件和《金陵药业股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，江苏泰和律师事务所（以下简称"本所"） 接受金陵药业股份有限公司（以下简称"公司"）的委托，指派律师（以下称"本 所律师"）出席公司 2025 年第二次临时股东大会（以下简称"本次股东大会" "会议"），并出具本法律意见书。 本所律师根据《股东会规则》第六条的要求，出席了本次股东大会并按照律 师行业公认的业 ...

Group 1 - The high-pressure oxygen chamber concept increased by 2.56%, ranking third among concept sectors, with five stocks rising, including Innovation Medical which hit the daily limit, and others like BeiYikang, Jinling Pharmaceutical, and Yingkang Life showing gains of 17.75%, 3.79%, and 1.25% respectively [1][2] - The main funds net inflow into the high-pressure oxygen chamber concept was 239 million yuan, with Innovation Medical receiving the highest net inflow of 226 million yuan, followed by Jinling Pharmaceutical and Yingkang Life with net inflows of 41.83 million yuan and 6.52 million yuan respectively [2][3] - The net inflow ratios for Innovation Medical, Jinling Pharmaceutical, and Yingkang Life were 11.04%, 8.08%, and 4.30% respectively, indicating strong investor interest in these stocks [3] Group 2 - The top gainers in the high-pressure oxygen chamber concept included Innovation Medical, Jinling Pharmaceutical, and Yingkang Life, while the top losers were Weiao Co., Samsung Medical, and Tiejian Heavy Industry, with declines of 1.74%, 0.92%, and 0.69% respectively [1][4] - The trading volume and turnover rates for the leading stocks in the high-pressure oxygen chamber concept were significant, with Innovation Medical showing a turnover rate of 30.10% and a trading volume of 22.62 million yuan [3]

截至8月7日收盘，仿制药一致性评价概念下跌1.34%，位居概念板块跌幅榜前列，板块内，千红制药跌 停，华海药业、亚太药业、联环药业等跌幅居前，股价上涨的有18只，涨幅居前的有润都股份、海辰药 业、*ST苏吴等，分别上涨9.98%、7.22%、4.63%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 稀土永磁 | 3.24 | 减肥药 | -1.70 | | 脑机接口 | 2.69 | CRO概念 | -1.66 | | 高压氧舱 | 2.56 | 创新药 | -1.41 | | 太赫兹 | 1.65 | 仿制药一致性评价 | -1.34 | | 血氧仪 | 1.62 | 重组蛋白 | -1.29 | | 存储芯片 | 1.40 | 中船系 | -1.28 | | MCU芯片 | 1.18 | 阿尔茨海默概念 | -1.18 | | 无线耳机 | 1.08 | 特钢概念 | -1.02 | | 汽车芯片 | 1.02 | 细胞免疫治疗 | -1.02 | | DRG/DIP | 1.00 | PET铜箔 | ...

Meeting Overview - The company will hold its second extraordinary general meeting of shareholders in 2025 on August 8, 2025, at 14:00 [2] - The meeting is convened by the company's board of directors, following the approval of the proposal to hold the meeting at the 19th meeting of the 9th board of directors [1][2] - The meeting complies with legal, regulatory, and company charter requirements [1] Voting Details - Shareholders can vote both in-person and online, with online voting available from 9:15 to 15:00 on August 8, 2025 [2][13] - The record date for shareholders eligible to attend the meeting is August 4, 2025 [3] - Only one voting method (in-person or online) can be chosen by shareholders, and duplicate votes will be counted as the first vote cast [2][8] Attendance and Registration - All shareholders registered with the China Securities Depository and Clearing Corporation Limited as of the record date can attend the meeting [3] - Registration can be done in person, by mail, or by fax, with a deadline of August 7, 2025, at 17:00 [9][10] - Specific documents are required for registration, including identification and proof of shareholding [11] Meeting Agenda - The proposals for the meeting have been approved by the board and supervisory committee [7] - Proposals 1 and 2 require a special resolution, needing more than two-thirds of the valid voting rights present at the meeting to pass [8] - Voting results will be disclosed publicly, with separate counting for small investors [8] Contact Information - The meeting will take place at the company's headquarters in Nanjing [6] - Contact details for the company include a phone number and fax for inquiries [13]

Meeting Overview - The company will hold its second extraordinary general meeting of shareholders in 2025 on August 8, 2025, at 14:00 [2] - The meeting will be convened by the company's board of directors, following the approval of the proposal to hold the meeting at the 19th meeting of the 9th board of directors [1][2] - The meeting complies with legal and regulatory requirements [1] Voting Details - Shareholders can participate in the meeting through both on-site and online voting [2] - The online voting will be available on August 8, 2025, from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 [2] - The record date for shareholders eligible to attend the meeting is August 4, 2025 [3] Attendance and Registration - All shareholders registered with the China Securities Depository and Clearing Corporation Limited as of the record date can attend the meeting [3] - Registration can be done in person, by mail, or by fax, with a deadline of August 7, 2025, at 17:00 [9] - Specific documents are required for registration, including identification and proof of shareholding [9][10] Meeting Agenda - The proposals to be discussed have been approved by the board and supervisory committee [8] - Proposals 1 and 2 require a special resolution, needing more than two-thirds of the valid voting rights held by attending shareholders to pass [8] - Voting results will be disclosed publicly, with separate counting for small investors [8] Contact Information - The meeting will take place at the company's headquarters located at 238 Central Road, Nanjing [6] - Contact details for the company include a phone number and fax for inquiries [11]